Oncology Corporate Profile
Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer. Unum’s lead program, based on its Antibody-Coupled T-cell Receptor (ACTR) technology, recently entered Phase I clinical testing to assess safety and efficacy.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|ATTCK20||chimeric monoclonal antibody (inhibits CD20)||Chronic Lymphocytic Leukemia (CLL)||I|
|ATTCK20||chimeric monoclonal antibody (inhibits CD20)||Non-Hodgkin's Lymphoma (NHL)||I|
View additional information on product candidates here »
12/14/2015 11:56 am
(Yahoo! Finance) Dec 14, 2015 - Unum Therapeutics, a company developing a universal cellular immunotherapy to treat multiple cancers, announced today that it has received unanimous approval by the National Institute of Health’s (NIH) Recombinant DNA Advisory Committee (RAC) for its first U.S.-based clinical trial.
7/27/2015 06:01 pm